Human Growth Hormone Market Size, Share, Trend, Forecast & Industry Analysis: 2022-2028
See less
Human Growth Hormone Market Size, Share, Trend, Forecast & Industry Analysis: 2022-2028
Human Growth Hormone Market is segmented by Product Type (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others),Distribution Channel Type (Hospital Pharmacies, Retail Pharmacies, E-Commerce), and Region (North America [The USA, Canada, and Mexico], Europe [Germany, France, The U.K., Russia, and Rest of Europe], Asia-Pacific [China, Japan, India, South Korea, and Rest of Asia-Pacific], and Rest of the World [Brazil, Saudi Arabia, Israel, and Others]).
Human Growth Hormone Market is segmented by Product Type (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others), Distribution Channel Type ...
“The Human Growth Hormone Marketwas estimated atUS$ 4.1 billion in 2021 and is expected to grow at a CAGR of 9.18%during2022-2028to reach US$ 8.9 billion by 2028.”
Human Growth Hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland. It is essential in growth, tissue repair, and metabolism. Thus, it is possible to conclude that HGH plays a role in stimulating the growth of children and adolescents through enhanced protein synthesis and cell proliferation. It assists in the body composition, muscle, and bones as well as metabolism in an adult's body.
HGH imbalance can therefore cause growth disorders, specifically, its excess leads to gigantism/acromegaly while deficiency causes growth and development problems. It is also clinically applied to the treatment of growth retardation in children, and some hormonal deficiency states in adults.
Human Growth Hormone Market Report Overview
Market Size in 2028
US$ 8.9 billion
Market Size in 2021
US$ 4.1 billion
Market Growth (2022-2028)
9.18% CAGR
Base Year of Study
2021
Trend Period
2016-2020
Forecast Period
2022-2028
Market Drivers
As mentioned by the American Academy of Pediatrics, the deficiency of this hormone in individuals is a rather rare pathological condition, which is characterized in one out of 3,000 to one out of 10,000 children in the United States.
Presently, HGH is widely utilized as an anti-aging drug among elder people and by athletes and bodybuilders as an anabolic drug. However, as per the USFDA, HGH is categorized as a prescription-only drug and is not approved for any anti-aging or performance-boost uses.
In addition, increased concerns among the populace about GH deficiency and treatment through human growth hormones are expected to fuel the government and private organizations’ activities for the global market.
Every year on the third Friday of February, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), an internationally affiliated nonprofit charitable organization with headquarters in the United States of America celebrates International Children’s Growth Awareness Day to educate on early identification and Management of growth hormone abnormalities in human beings with particular emphasis on the children.
However, the high cost of associated therapies that involve HGH and various complications that come with it may act as a restraining factor to the market during the forecast period. For instance, the UPMC Children’s Hospital of Pittsburgh affirms that the side effects of GH hormone therapy include knee, hip, or other joint pains, rashes, swellings or hives, and high blood sugar levels.
Want to get more details about the drivers? Register Here
Segments Analysis
Segmentations
List of Sub-Segments
Dominant and Fastest-Growing Segments
Application Type
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others
The Growth Hormone deficiency category dominated the market during the forecast period.
The hospital pharmacy segment dominates the market during the forecast period.
Region Analysis
North America, Europe, Asia-Pacific, and the Rest of the World
North America is expected to account for the greatest share during the forecast period.
By Application Type
“The GH deficiency category accounts for a maximum share during the forecast period.”
The human growth hormone market is segmented into growth hormone deficiency, turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age, and others. The GH deficiency category dominated the market and is projected to continue to do so throughout the forecast period. This is due to increased awareness regarding the early detection and treatment of GH insufficiency in people, as well as the entry of novel medications into the HGH market.
For example, Ascendis Pharma A/S received an Orphan Designation from the European Commission (EC) in October 2018 for its investigational long-acting GH medication for humans, TransCon HGH, which is recommended for the treatment of pediatric GH deficiency.
Similarly, Ferring Pharmaceuticals Inc. got USFDA approval in January 2018 for Zomacton (somatropin), a novel recombinant HGH intended for the treatment of adults with GH insufficiency. The GH deficiency category is further subdivided into adult and pediatric GH deficiency, with the latter expected to dominate the market over the projection period due to a rising number of pipeline medications.
For example, Pfizer Inc. and its partner OPKO Health Inc. stated in October 2019 that their Phase III research of Somatrogon in pre-pubertal children with HGH fulfilled its primary endpoint of non-inferiority to daily somatropin. Turner's syndrome accounted for the second-largest market share in 2021 and is expected to emerge as a profitable category during the projected period. This can be explained by
By Distribution Channel Type
“The hospital pharmacy segment dominates the market during the forecast period.”
The market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacy segment held a sizable market share. This large percentage is ascribed to an increase in hospital visits due to increased human awareness of GH insufficiency and therapy. According to the Children's Hospital of Philadelphia (CHOP), growth hormone prescriptions have climbed from 5.1 patients per 10,000 beneficiaries in 2001 to 14.6 patients per 10,000 in 2016.
Regional Analysis
“North America dominates the market during the forecast period.”
The human growth hormone market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World. Because of variables such as attractive reimbursement scenarios, established healthcare infrastructure, considerable government initiatives, and expanding healthcare awareness, North America is expected to account for the greatest share.
Furthermore, the presence of significant firms in the region facilitates access to innovative pharmaceuticals, which benefits the North American market. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are three significant competitors based in the United States that provide a wide range of human GH medicines in the region.
Over the forecast period, Asia-Pacific is expected to grow at a rapid pace.
Key competitors are focusing on attaining a significant market share in potential Asia-Pacific nations such as Japan and China through product approval and launch. For example, in March 2017, Novo Nordisk A/S, a Danish pharmaceutical company, began a phase III clinical trial in Japan for their HGH somapacitan, which is designed for the treatment of adults with growth hormone insufficiency.
Want to know which region offers the best growth opportunities?Register Here
Key Players
The market is highly populated with the presence of several local, regional, and global players. Most of the major players compete in some of the governing factors including price, product offerings, regional presence, etc.
The following are the key players in the human growth hormone market (arranged alphabetically).
Note:The above list does not necessarily include all the top players in the market.
Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com
Report Features
This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.
What Deliverables Will You Get in this Report?
Key questions this report answers
Relevant contents in the report
How big is the sales opportunity?
In-depth Analysis of the Human Growth Hormone Market
How lucrative is the future?
The market forecast and trend data and emerging trends
Which regions offer the best sales opportunities?
Global, regional, and country-level historical data and forecasts
Which are the most attractive market segments?
Market Segment Analysis and Forecast
Who are the top players and their market positioning?
Porter’s five forces analysis, PEST analysis, Life cycle analysis
What are the factors affecting the market?
Drivers & challenges
Will I get the information on my specific requirements?
10% free customization
Research Methodology
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.
We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.
Customization Options
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Detailed profiling of additional market players (up to 3 players).
SWOT analysis of key players (up to 3 players).
Market Segmentation
Current market segmentation of any one of the product types by application type.
Competitive Benchmarking
Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.
Recent Market News
Several businesses are working on long-acting human growth hormones. Mergers, partnerships, as well as acquisitions are significant methods used by the market's leading players to extend their geographical scope and provide access to their products. For example,
Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Sandoz International GmbH (Novartis AG), Merck KGaA, Genentech, Inc. (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, and Ipsen are some of the market's prominent participants.
In October 2018, Novo Nordisk and Strongbridge Biopharma agreed to buy the rights to MACRILEN in the United States and Canada. MACRILEN (macimorelin) is the first and only FDA-approved oral medication for the diagnosis of adult growth hormone insufficiency.
Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:
The human growth hormones market is likely to be driven by a robust product pipeline and extensive R&D initiatives for the development of innovative growth hormone therapies. In September 2018, Novo Nordisk presented Phase II clinical trial data for Somapacitan, an experimental GH medication recommended for treating pediatric growth hormone insufficiency.
Furthermore, Ascendis Pharma A/S announced Phase III clinical trial findings for their TransCon HGH, indicated for juvenile growth hormone insufficiency, in May 2019.
Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences are also engaging in R&D initiatives to develop innovative human growth hormone therapy.
LOADING
LOADING
×
Please enter your contact details. It will allow our analysts to reach out to you.
Human Growth Hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland. It is essential in growth, tissue repair, and metabolism. Thus, it is possible to conclude that HGH plays a role in stimulating the growth of children and adolescents through enhanced protein synthesis and cell proliferation. It assists in the body composition, muscle, and bones as well as metabolism in an adult's body. HGH imbalance can therefore cause growth disorders, specifically, its excess leads to gigantism/acromegaly while deficiency causes growth and development problems. It is also clinically applied to the treatment of growth retardation in children, and some hormonal deficiency states in adults.
The major players in the human growth hormone market are AnkeBio Co. Ltd, EMD Serono Inc., F. Hoffmann-La Roche Ltd, Ferring BV, Ipsen SA, Eli Lilly and Company, Novo Nordisk AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH (Novartis AG), Strongbridge Biopharma, GeneScience Pharmaceuticals Co. Ltd, Sinobioway Hygene Biomedicine Co. Ltd, Aeterna Zentaris, LG Life Sciences.